Alexion Pharmaceuticals Inc (ALXN) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2012

Earnings Press Release
10-K Annual Report
10-K YoY Changes
Alexion Pharmaceuticals, Inc.
Ticker: ALXN CIK: 899866

Contacts :



Alexion Pharmaceuticals, Inc. Irving Adler Executive Director, Corporate Communications (203) 271-8210	Alexion Pharmaceuticals, Inc. Kim Diamond (Media) Director, Corporate Communications (203) 439-9600	Rx Communications (Investors) Rhonda Chiger (917) 322-2569

Alexion Reports Fourth Quarter and Full Year 2012 Results

- Soliris® (eculizumab) Net Product Sales Increased 45 Percent to $1.134 Billion in 2012 -

- Continued Steady Growth of Soliris in PNH -

- aHUS Launch Progresses with Increasing Number of New Patients Starting on Soliris -

- Pipeline Advances with Five Therapeutic Candidates Targeting Severe and Ultra-Rare Disorders -

Fourth Quarter 2012 Financial Highlights:


•	Q4 2012 net product sales increased 41 percent to $320.5 million, compared to $227.6 million in Q4 2011.


•	Q4 2012 GAAP net income increased 68 percent to $81.0 million, or $0.40 per share, compared to Q4 2011 GAAP net income of $48.2 million, or $0.25 per share.


•	Q4 2012 non-GAAP net income increased 52 percent to $122.3 million, or $0.60 per share, compared to Q4 2011 non-GAAP net income of $80.5 million, or $0.41 per share.

Full-Year 2012 Financial Highlights:


•	2012 net product sales increased 45 percent to $1.134 billion, compared to $783.4 million in 2011.


•	2012 GAAP net income increased 45 percent to $254.8 million, or $1.28 per share, compared to 2011 GAAP net income of $175.3 million, or $0.91 per share.


•	2012 non-GAAP net income increased 60 percent to $425.2 million, or $2.13 per share, compared to 2011 non-GAAP net income of $266.1 million, or $1.38 per share.

CHESHIRE, Conn., February 14, 2013 --

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the quarter and year ended December 31, 2012. For the three months ended December 31, 2012, Alexion Pharmaceuticals, Inc. ("Alexion" or the

The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, February 14, 2013 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Alexion Pharmaceuticals, Inc..

Continue

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/899866/000089986613000060/alxn10k12312012.htm